James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Universal Health Services, Inc. (UHS), Encana Corp (USA) (ECA) and Express Scripts Holding Company (ESRX) Are 3 of Today’s Worst Stocks

Encana (ECA), Express Scripts (ESRX) and Universal Health Services (UHS) were upended by rampant worry on Wednesday.

Don’t Count Oracle Corporation (ORCL) Stock Out So Easily

Oracle stock is looking more promising every day, but it's still too soon to bet the farm on it. ORCL stock needs some organic growth first.

Bank of America Corp (BAC) Stock Is a Screaming Buy on Any Dip

Bank of America (BAC) is entering the perfect bullish storm. If you see a pullback in BAC stock anytime soon, buy it.

The Best Reason to Own Amazon.com, Inc. (AMZN) Stock Right Now

Amazon.com (AMZN) just eradicated a brewing concern about its cloud division. And that means more to AMZN stock than you think.

Why Alexion Pharmaceuticals, Inc. (ALXN), Inovalon Holdings Inc (INOV) and Southern Copper Corp (SCCO) Are 3 of Today’s Worst Stocks

Southern Copper (SCCO), Alexion Pharmaceuticals (ALXN) and Inovalon Holdings (INOV) couldn't win for losing on Tuesday, though for understandable reasons.